4,901 trials
Prostate Cancer · Endometriosis
Primary: Cmax: Maximum Observed Plasma Concentration of TAK-385 on Day 1 — 10.9; 20.1 ng/mL
Solid Tumours
Primary: Effect of Olaparib on Exposure to Tamoxifen - Cmax ss — 130.3; 154.2; 162.9; 149.1 mcg/mL
Solid Tumor or Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 25 milligram (mg)
Rheumatoid Arthritis
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events (AEs) [Clinically Significant Events] — 6; 5; 16; 3 participants
Advanced Solid Malignancy, · Safety and Tolerability, · Pharmacokinetics, Pharmacodynamics,
Primary: Ratio of Css,Max for Day 4 to Day 11 — 1.02; 0.67 Ratio
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
Japanese Healthy Adult Males
Primary: Cmax: Maximum Observed Plasma Concentration for TAK 272F and TAK 272-Metabolite (M-I) in Cohort 1 — 387.8; 780.3; 10.02; 0.9550 nanogram per milliliter (ng/mL)
Parkinson's Disease
Primary: Dose Adjusted Area Under the Curve (AUC) (0-14h) for Levodopa — 40.6; 29.4 h*ng/mL/mg — p=<0.0001
Safety · Tolerability · Pharmacokinetics
Primary: Safety and Tolerability Based on the Number of Participants With Adverse Events and Comparison of Baseline and Post Dose Parameters — 9; 1 participants
Healthy
Primary: Area Under the Plasma Concentration of BCD-085-time Curve From Zero (0) Hours to 1344 Hours After the Single Subcutaneous Injection of BCD-085 — 594222.00; 2262670.25…
Healthy
Primary: Maximum Concentration of Adalimumab After Single SC Injection of BCD-057/Humira — 4426; 4522 ng/ml
Seasonal Allergic Rhinitis
Primary: Average of Rhinoconjunctivitis Total Symptom Score (ARTSS) ]0-4] Hours — 4.88; 6.84 Units on a scale (range: 0 to 18) — p=0.0003
Cancer
Primary: Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib — 23.6; 30.7; 30.5; 20.5 micromolar
Healthy
Primary: AUCt for Serum Deferiprone and Deferiprone 3-O-glucuronide — 63.5; 52.3; 71.1; 171.9 mcg*h/mL